PROSPECTs Futile For Bavarian Nordic's Prostvac Cancer Vaccine

The Phase III PROSPECT study's data monitoring committee decides against continuing after interim analysis. The fall-out could hit Bavarian Nordic’s CV301 too.

group of businessman in black suit and holding red arrow down graph
• Source: Shutterstock

Bavarian Nordic AS's lead investigational product, the prostate cancer vaccine Prostvac (rilimogene galvacirepvec), has failed at the Phase III stage, sending the firm's share price down by more than 48% to DKK228.5 on Sept. 15, and raising concerns over potential implications for another of its candidate vaccines.

The PROSPECT study's independent data monitoring committee has deemed continuing with the trial in metastatic castration-resistant prostate cancer futile, based...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category